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Abstract
Background: Sirt6 has been implicated in the regulation of hepatic lipid metabolism and the development of hepatic
steatosis. The aim of this study was to address the potential role of Sirt6 in the protective effects of rosiglitazone (RGZ) on
hepatic steatosis.
Methods: To investigate the effect of RGZ on hepatic steatosis, rats were treated with RGZ (4 mg?kg
21?day
21) by stomach
gavage for 6 weeks. The involvement of Sirt6 in the RGZ’s regulation was evaluated by Sirt6 knockdown in AML12 mouse
hepatocytes.
Results: RGZ treatment ameliorated hepatic lipid accumulation and increased expression of Sirt6, peroxisome proliferator-
activated receptor gamma coactivtor-1-a (Ppargc1a/PGC1-a) and Forkhead box O1 (Foxo1) in rat livers. AMP-activated
protein kinase (AMPK) phosphorylation was also increased by RGZ, accompanied by alterations in phosphorylation of LKB1.
Interestingly, in free fatty acid-treated cells, Sirt6 knockdown increased hepatocyte lipid accumulation measured as
increased triglyceride contents (p=0.035), suggesting that Sirt6 may be beneficial in reducing hepatic fat accumulation. In
addition, Sirt6 knockdown abolished the effects of RGZ on hepatocyte fat accumulation, mRNA and protein expression of
Ppargc1a/PGC1-a and Foxo1, and phosphorylation levels of LKB1 and AMPK, suggesting that Sirt6 is involved in RGZ-
mediated metabolic effects.
Conclusion: Our results demonstrate that RGZ significantly decreased hepatic lipid accumulation, and that this process
appeared to be mediated by the activation of the Sirt6-AMPK pathway. We propose Sirt6 as a possible therapeutic target for
hepatic steatosis.
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Introduction
Hepatic steatosis is a relatively benign and early condition of
nonalcoholic fatty liver disease (NAFLD), which is strongly
associated with obesity and insulin resistance [1,2]. But, when
accompanied by other metabolic disorders, it can progress to
severe stages of NAFLD; steatohepatitis, cirrhosis and hepatocel-
lular carcinoma [3–5].
Thiazolidinediones (TZD) are agonists of peroxisome prolifera-
tor-activated receptor gamma (PPARc), a nuclear transcription
factor primarily involved in insulin action, lipid and glucose
metabolism, and energy homeostasis [6,7]. TZD-activated PPARc
improves insulin sensitivity in most tissues, but affects lipid
metabolism in a cell- and tissue-specific manner. In adipose tissue,
TZD-activated PPARc stimulates adipocyte differentiation and
induces lipogenic enzymes, thereby increasing fat storage, especially
into subcutaneous adipose tissue [8–10]. This sequestration of lipid
into adipose tissue decreases circulating levels of triglyceride (TG)
and free fatty acids (FFA), thus decreasing lipid uptake in the liver.
In addition, TZD stimulates fatty acid oxidation and inhibits
excessive lipolysis and fatty acid synthesis in the liver, resulting in
reduced hepatic fat contents in both rodents and humans [11–13].
Although the link between TZD and hepatic steatosis has become
more evident, the underlying mechanism is poorly understood.
Several lines of evidence suggest that TZD activates AMP-activated
protein kinase (AMPK) by both PPARc-dependent and -indepen-
dent pathways, implying that AMPK may be a key regulator of the
beneficial metabolic effects of TZD [14–17].
Sirtuins are a family of proteins with NAD
+-dependent deacety-
lase and ADP-ribosyltransferase activities. They control key cellular
and physiological processes including apoptosis, energy homeostasis,
mitochondrial function and longevity [18]. Seven mammalian
PLoS ONE | www.plosone.org 1 February 2011 | Volume 6 | Issue 2 | e17057sirtuins (Sirt1-7) have been characterized according to their distinct
localization patterns and biological functions [18,19], and have been
suggested as potential therapeutic targets for metabolic syndrome
[20]. Sirt1 is a well-studied nuclear sirtuin with beneficial metabolic
effects, and it has been implicated in the improvement of hepatic
steatosis[21,22].Sirt1overexpressioninhigh-fatdiet-fedmiceresults
in improved glucose tolerance and protection from hepatic steatosis
and inflammation compared with wild-type controls [22]. Several
lines of evidence suggest that Sirt1 may function inpart by activating
AMPK [23,24], which is one of the suggested mechanisms
underlying TZD’s beneficial effects. Similarly, Sirt6 is also localized
in the nucleus and may also be involved in metabolic regulation.
Sirt6-deficient mice have an aging phenotype and metabolic defects
in glucose homeostasis, and eventually die at about four weeks of age
[25]. Interestingly, transgenic mice overexpressing Sirt6 are
protected from hepatic fat accumulation and other metabolic
damages induced by a high-fat diet [26]. Considering the previous
findings implicating AMPK in TZD’s beneficial effects, and the
potential interdependence of AMPKand sirtuins, we speculated that
TZD may protect against hepatic steatosis by activating the Sirt6-
AMPK pathway.
This study was designed to test whether Sirt6 contributes to the
protective effects of the TZD rosiglitazone (RGZ) on hepatic
steatosis. Using a rat model of moderate obesity and insulin
resistance and a cell model of hepatocyte steatosis, we report up-
regulation of adiponectin, Sirt6, peroxisome proliferator-activated
receptor gamma coactivtor-1-a (Ppargc1a/PGC1-a) and forkhead
box O1 (Foxo1), as well as increases in both LKB1 and AMPK
activities upon RGZ treatment. The functional relevance of Sirt6-
stimulated AMPK activation in the RGZ’s regulation on hepatic
fat accumulation was further investigated by RNA interference
(RNAi)-mediated Sirt6 knockdown in AML12 mouse hepatocytes.
Sirt6 knockdown abolished the effects of RGZ on hepatocyte fat
accumulation and the Sirt6-AMPK pathway, suggesting that Sirt6
is involved in RGZ-mediated metabolic effects. Collectively, these
data demonstrate that attenuation of hepatic steatosis by RGZ is
likely mediated by the activation of the Sirt6-AMPK pathway,




Male Otsuka Long-Evans Tokushima Fatty (OLETF) rats and
age-matched Long-Evans Tokushima Otsuka (LETO) rats were
provided by Otsuka Pharmaceutical (Tokushima, Japan). Rats
were maintained in a temperature- and humidity-controlled room
with a 12 h light/dark cycle and fed PicoLab Rodent Diet 20 5053
(5% wt/wt fat; Purina Mills, Richmond, IN, USA) with unlimited
access to food and water. To investigate the effect of RGZ on
hepatic steatosis, total 18 rats at about 32 weeks of age were
treated with RGZ (4 mg?kg
21?day
21; Cayman, Ann Arbor, MI,
USA) or with PBS as control vehicle, via stomach gavage for 6
weeks. The study protocol conformed to the specifications outlined
in the National Institutes of Health’s Guiding Principles for the
Care and Use of Laboratory Animals and was approved by the
Institutional Animal Care and Use Committee of the Sungkyunk-
wan University Kangbuk Samsung Hospital (Approval ID:
201010013).
Blood and Tissue Collection
Thirty eight-week-old LETO and OLETF rats were anesthe-
tized with intraperitoneal Zoletil/Rompun after an overnight
fast, and all efforts were made to minimize suffering. Blood was
collected from the abdominal aorta. After blood collection, tissues
were harvested and stored at 280uC until further analysis.
Cells and Culture Conditions
AML12 mouse hepatocytes (American Type Culture Collec-
tion, Manassas, VA, USA) were cultured in DMEM/F-12 media
(Invitrogen, Carlsbad, CA, USA) supplemented with 10% FBS,
antibiotics (100 units/ml penicillin and 100 mg/ml streptomycin),
Table 1. Primers sequences used in real-time RT-PCR.
Name of primers Forward Reverse UPL No.
mAdipoq ggagagaaaggagatgcaggt ctttcctgccaggggttc 17
mPpara ctgagaccctcggggaac aaacgtcagttcacagggaag 91
mPparg gaaagacaacggacaaatcacc gggggtgatatgtttgaacttg 7
mSirt1 tcgtggagacatttttaatcagg gcttcatgatggcaagtgg 104
mSirt6 acgcggataagggcaagt ctcccacaccttgcgttc 82
mPpargc1a gaaagggccaaacagagaga gtaaatcacacggcgctctt 29
mFoxo1 cttcaaggataagggcgaca gacagattgtggcgaattga 11
mActb ggatgcagaaggagattactgc ccaccgatccacacagagta 63
rAdipoq tggtcacaatgggataccg cccttaggaccaagaacacct 80
rPpara tgcggactaccagtacttaggg gctggagagagggtgtctgt 116
rPparg ggtgaaactctgggagatcct aatggcatctctgtgtcaacc 115
rSirt6 acctaacgctcgctgatga gaggtacccagggtgacaga 18
rPpargc1a aatttttcaagtctaactatgcagacc aaaatccagagagtcatacttgctc 38
rFoxo1 tcaggctaggagttagtgagca ggggtgaagggcatcttt 68
rGapdh gagatcaacgtgttccagtgc cttccaccacgtagggattc 1
mActb, mouse b-actin; mAdipoq, mouse adiponectin; mFoxo1, mouse forkhead box O1; mPpara, mouse peroxisome proliferator-activated receptor alpha; mPparg,
mouse peroxisome proliferator-activated receptor gamma; mPpargc1a, mouse peroxisome proliferator-activated receptor gamma coactivtor-1-a; rGapdh, rat
glyceraldehyde-3-phosphate dehydrogenase; UPL, Universal ProbeLibrary system.
doi:10.1371/journal.pone.0017057.t001
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selenium (Invitrogen). For the induction of hepatocyte steatosis,
subsets of AML12 hepatocytes were treated with palmitic acid
(250 mM; Sigma-Aldrich, St Louis, MO, USA; FFA) for 48 h. This
was followed by treatment with FFA and/or RGZ (10 mM) for an
additional 24 h.
RNAi-mediated gene silencing was performed according to the
manufacturer’s instructions. AML12 cells were transfected with
negative control siRNA (Stealth RNAi negative control duplexes;
Invitrogen) or Stealth RNAi siRNA targeting Sirt6 using
Lipofectamine (Invitrogen). After 24 h of transfection, subsets of
cells were incubated with FFA for 48 h to induce hepatocyte
steatosis. Cells were then cultured in the presence or absence of
FFA and/or RGZ for an additional 24 h.
Histological Analysis
Livers were fixed overnight in 10% (vol./vol.) zinc formalin,
dehydrated in a graded series of alcohol washes, cleared in toluene
and embedded in paraffin. Using a microtome, 5 mm sections were
generated, collected on slides, and then stained with hematoxylin
and eosin.
NAFLD Activity Score (NAS)
The NAS is used to assess the severity of NAFLD, according to
Kleiner et al. [27]. The NAS evaluates three features of NAFLD
and is calculated by adding the individual scores: steatosis
(,5%=0, 5–33%=1, 33–66%=2, .66%=3), lobular inflam-
mation (none =0, ,2 foci =1, 2–4 foci =2, .4 foci =3), and
ballooning (none =0, few =1, many =2). Liver sections were
evaluated for NAS by a pathologist blinded to the study.
Metabolic Parameters
Glucose, TG and glycerol concentrations were measured by
enzymatic assays (Sigma). FFA concentrations in serum, tissues,
and cell extracts were measured by a commercial kit from Wako
(Wako Pure Chemical Industries, Osaka, Japan). Total cholesterol
(TC) concentrations were measured by a cholesterol assay kit
(Cayman). All values of TG, glycerol, FFA, and TC in liver and
cell extracts were normalized to protein concentrations. Commer-
cially available ELISA kits were used for the measurement of
adiponectin (B-Bridge International, Mountain View, CA, USA)
and insulin (Crystal Chem, Downers Grove, IL, USA).
Isolation of Total RNA and Quantitative RT-PCR
Total RNA was isolated from cells and tissues with the use of a
PureLink RNA Mini Kit (Invitrogen). Reverse transcription was
performed using a High-Capacity RNA-to-cDNA kit (Applied
Biosystems, Foster City, CA, USA) following the manufacturer’s
instructions. mRNA expression was quantified by real-time PCR
(LightCycler 480 system; Roche, Indianapolis, IN, USA).
Synthesized cDNA was mixed with LightCycler 480 Probes
Master Mix (Roche), and with a gene-specific primer and probe
mixture (Universal ProbeLibrary system; UPL; Roche; Table 1).
Individual reactions for target and b-actin (Actb) or glyceraldehyde-
3-phosphate dehydrogenase (Gapdh) were carried out separately
with negative controls lacking cDNA. The conditions used were as
follows: 95uC for 10 min, followed by 40 cycles of denaturation
(95uC for 10 s) and annealing/extension (60uC for 20 s). The cycle
number for the threshold of detection was determined by
Table 2. The effects of rosiglitazone (RGZ) on body weights,
food intake and fat pad weights.
LETO OLETF
Control RGZ Control RGZ
Body weight
Baseline (g) 511614 51569 603623 611621
Post-treatment (g) 522685 5 9 617 530615 635643
Weight change (g) 12611 45616 273610 25630*
Food intake (g) 23.160.5 23.462.3 39.260.4 37.960.6
Fat pad weights (%) 3.960.4 4.860.4 5.760.8 11.361.2*
Subcutaneous fat (%) 0.960.1 1.460.1* 0.960.2 1.860.4*
Epididymal fat (%) 1.360.2 1.560.2 1.460.1 1.960.3
Mesenteric fat (%) 0.660.0 0.560.0* 0.660.1 0.960.1
Retroperitoneal fat (%) 1.260.1 1.460.2 2.960.4 6.760.6*
Data are expressed as means6SEM (n=4–5 per group). Fat pad weights are
expressed as a percentage of fasted body weight. *p,0.05 vs controls.
doi:10.1371/journal.pone.0017057.t002
Figure 1. Rosiglitazone (RGZ) improves hepatic steatosis and
nonalcoholic fatty liver disease (NAFLD) in OLETF rats. (A)
Representative photographs of hematoxylin and eosin-stained sections
of livers. Arrows indicate macrovesicular- and microvesicular steatosis.
Scale bar, 100 mm. Original magnification, x200 for light microscopy. (B)
NAFLD activity score (NAS). N.D., not detected; LE, LETO; OL, OLETF; R,
RGZ; Data for NAS are means6SEM (n=4–5 per group). *p,0.05 vs
controls (CON or C).
doi:10.1371/journal.pone.0017057.g001
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target was normalized to that of the Actb or Gapdh gene and
expressed as fold change relative to controls.
Western Blot Analysis
Total protein was isolated from tissues and cells by homoge-
nization in cold RIPA lysis buffer (Amresco, Solon, OH, USA)
containing protease inhibitors and phosphatase inhibitors (Roche).
The lysates were centrifuged, and supernatants were collected and
subjected to western blot analysis. Protein concentrations were
measured using the Bio-Rad protein assay (Bio-Rad Laboratories,
Hercules, CA, USA) according to the manufacturer’s instructions.
Western blotting was performed by denaturing 50 mg of protein at
95uC for 5 min in Laemmli sample buffer (Fermentas, Burlington,
Ontario, Canada). Sample proteins were separated by SDS-PAGE
and transferred to a polyvinylidene difluoride membrane.
Membranes were blocked in 5% nonfat dry milk in Tris-buffered
saline/Tween-20 (50 mM Tris, pH 7.5, 500 mM sodium chloride,
and 0.05% Tween-20) for 1 h at room temperature. Membranes
were incubated overnight at 4uC with primary antibodies for
Foxo1, insulin receptor (IR), IR substrate1 (IRS1), Akt, phospho-
Akt (Ser473), AMPKa, phospho-AMPKa (Thr172), LBK1,
phospho-LKB1 (Ser428) (Cell Signaling Technology, Danvers,
MA, USA), PGC1-a, b-actin (Santa Cruz Biotechnology, Santa
Cruz, CA, USA), phospho-Foxo1 (Ser249) (Invitrogen), Sirt6,
phospho-IR (Tyr1158, Tyr1162, and Tyr1163), phospho-IRS1
(Tyr612), and glucose transporter 1 (GLUT1) (Abcam, Cam-
bridge, UK). Membranes were then exposed to an anti-rabbit
secondary antibody conjugated to horseradish peroxidase (Santa
Cruz Biotechnology) for 1 h at room temperature. Signals were
detected by chemiluminescence using the ECL detection reagent
(GE Healthcare, Piscataway, NJ, USA). The bands were scanned
by a Geliance 600 Imaging System (PerkinElmer, Waltham, MA,
USA) with a cooled 12-bit camera, and quantified by densitom-
etry. Levels of phosphorylated Foxo1 at Ser249, AMPKa
(Thr172), LKB1 (Ser428), IR at three tyrosine residues
(Tyr1158, Tyr1162, and Tyr1163), IRS1 at Tyr612, and Akt at
Ser473, were normalized to values for Foxo1, AMPKa, LKB1, IR,
IRS1, and Akt, respectively. Levels of Sirt6, PGC1-a, and GLUT1
were normalized to values for b-actin.
Figure 2. The effects of rosiglitazone (RGZ) on serum and liver metabolic parameters. Values of liver free fatty acids (FFA), triglycerides
(TG), and total cholesterol (TC) were normalized with respect to protein concentrations. Data are means6SEM (n=4–5 per group). *p,0.05 vs
controls (CON).
doi:10.1371/journal.pone.0017057.g002
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All statistical analyses were performed using PASW Statistics 17
(SPSS Inc., Chicago, IL, USA). Data are expressed as mean-
s6SEM. Student’s t test or one-way ANOVA was performed to
compare groups. Statistical significance was defined as p,0.05.
Results
RGZ Improved Hepatic Steatosis in OLETF Rats
To address the role of Sirt6 in the beneficial effects of RGZ,
we first determined the metabolic effects of RGZ on hepatic
Figure 3. Rosiglitazone (RGZ) alters the expression of Sirt6 and other related targets in rat livers. Gene expression of (A) adiponectin
(Adipoq), (B) peroxisome proliferator-activated receptor alpha (Ppara), (C) PPAR gamma (Pparg), (D) Sirt6, (E) peroxisome proliferator-activated
receptor gamma coactivtor-1-a (Ppargc1a), and (F) forkhead box O1 (Foxo1). The expression levels were normalized with respect to those of
glyceraldehyde-3-phosphate dehydrogenase (Gapdh). (G) Representative western blots for Sirt6, peroxisome proliferator-activated receptor gamma
coactivtor-1-a (PGC1- a), phosphorylated Foxo1 at Ser249 (pFoxo1), Foxo1, and b-actin. (H) Densitometric analysis of Sirt6, PGC1- a, and pFoxo1. The
expression of Sirt6 and PGC1- a was normalized to values for b-actin. Levels of phosphorylated Foxo1 at Ser249 were normalized to values for Foxo1.
Data are means6SEM (n=4–5 per group). *p,0.05 vs controls (CON).
doi:10.1371/journal.pone.0017057.g003
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weight of OLETF control rats decreased, which is due to
aggravation of diabetic conditions (Table 2). However, there was
a significant increase in the body weight of RGZ-treated OLETF
rats without altered food intake (Table 2). Total fat weights of
RGZ-treated OLETF rats were significantly higher than those of
control OLETF rats (Table 2), consistent with previous findings
that RGZ leads to increased fat storage into adipose tissue [8–10].
There was a significant increase in subcutaneous fat and
mesenteric fat in LETO rats, and in subcutaneous fat and
retroperitoneal fat in OLETF rats with RGZ treatment, but the
patterns of increases in the other fat pads were not statistically
significant.
Histological analyses demonstrated that OLETF livers were
filled with large lipid droplets and there was evidence of both
macrovesicular- and microvesicular steatosis, while LETO livers
showed normal morphology (Figure 1A). RGZ-treated OLETF
livers showed a significant reduction in the degree of steatosis
(p=0.040), and a trend of decrease in NAFLD activity score
compared with untreated OLETF rats (p=0.083; Figure 1B). In
addition, serum levels of glucose and insulin were reduced by
RGZ treatment in OLETF rats (Figures 2A, B). RGZ treatment
increased serum adiponectin concentrations in both LETO and
OLETF rats (Figure 2C). Levels of FFA, TG, and TC in serum
and livers were decreased in RGZ-treated OLETF rats compared
with untreated rats (Figures 2D–I). Reduced lipid droplets and
Figure 4. Rosiglitazone (RGZ) activates the LKB1-AMP-activated protein kinase (AMPK) pathway in rat livers. (A) Representative
western blots for phosphorylated LKB1 at Ser428 (pLKB1), LKB1, phosphorylated AMPKa at Thr172 (pAMPKa), pAMPKa, and b-actin. (B) Densitometric
analysis of pLKB1 and pAMPKa. Levels of phosphorylated LKB1 at Ser428 and AMPKa at Thr172 were normalized to values for LKB1 and AMPKa,
respectively. Data are means6SEM (n=4–5 per group). *p,0.05 vs controls (CON).
doi:10.1371/journal.pone.0017057.g004
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hepatic steatosis [13].
RGZ Up-regulated Gene Expression of Sirt6 and Increased
phosphorylation levels of LKB1 and AMPK in OLETF Rat
Livers
Next, we explored the involvement of Sirt6 and AMPK in the
functional regulation of RGZ by investigating whether RGZ alters
expression of Sirt6 and other related genes in the liver. Gene
expression of adiponectin (Adipoq), PPAR alpha (Ppara), and Pparg
was significantly increased in both LETO and OLETF rat livers
with RGZ (Figures 3A–C). Moreover, RGZ treatment significantly
up-regulated expression of Sirt6, Ppargc1a/PGC1-a, and Foxo1
in OLETF rat livers (Figures 3D–H). AMPK plays a key role in
the regulation of lipid metabolism by controlling fatty acid
oxidation and synthesis, and its activation is reported to be
affected by Sirt1 [23,24]. The phosphorylation levels of AMPK at
Thr172 and LKB1 at Ser428 were significantly increased by RGZ
treatment (Figure 4), suggesting that the Sirt6-AMPK pathway
may be involved in the beneficial effects of RGZ on hepatic
steatosis.
RGZ-Dependent Reduction of Lipid Accumulation and
Activation of the Sirt6-AMPK Pathway Is Abrogated by
Knockdown of Sirt6 in AML12 Mouse Hepatocytes
The in vivo experiments suggested that coordinated regulation of
adiponectin, Sirt6, and AMPK may play a role in RGZ’s
protective action. The up-regulation of Sirt6 and its related genes
as well as the activation of LKB1 and AMPK by RGZ led us to
hypothesize that RGZ may exert its positive effects by acting on
Sirt6. We therefore performed RNAi-mediated gene silencing by
transfecting AML12 cells with siRNA oligos targeting Sirt6.
Subsets of cells were incubated with FFA for 48 h to induce
hepatocyte steatosis, and then treated with FFA and/or RGZ for
additional 24 h. FFA incubation for 72 h induced hepatocyte
steatosis with a significant increase in TG and FFA (Figure 5). As
expected, RGZ treatment significantly reduced hepatocyte lipid
accumulation. However, Sirt6 knockdown significantly increased
TG and FFA levels in FFA-treated hepatocytes and diminished the
effects of RGZ on hepatocyte lipid accumulation (Figure 5). The
mRNA and protein expression patterns of targets that were
investigated were similar to those found in vivo (Figure 6). Sirt6
knockdown was confirmed by a significant repression of its mRNA
and protein expression (Figures 6D, G, H). Gene expression of
Adipoq, Ppara, and Pparg was up-regulated by RGZ and the up-
regulation was not altered with Sirt6 knockdown, suggesting that
these may act as upstream regulators of Sirt6 (Figures 6A–C).
However, the RGZ-mediated up-regulation of Ppargc1a/PGC1-a
and Foxo1 was abolished with Sirt6 knockdown, suggesting that
Ppargc1a/PGC1-a and Foxo1 are downstream targets of Sirt6 in
AML12 mouse hepatocytes (Figures 6E–H). Sirt6 knockdown has
no effect on Sirt1 mRNA expression level (control siRNA,
1.0760.31; Sirt6 siRNA, 1.1160.21 relative fold change;
p=0.888).
Mediators involved in insulin signaling were analyzed to see
whether Sirt6 knockdown in AML12 mouse hepatocytes affects
the insulin signaling pathway. As expected, RGZ increased protein
expression of GLUT1 and phosphorylation levels of IR at three
tyrosine residues (Tyr1158, Tyr1162, and Tyr1163), IRS1 at
Tyr612, and Akt at Ser473 in the presence or absence of FFA
(Figure S1). Sirt6 knockdown increased protein expression of
GLUT1 and phosphorylation levels of IRS1 at Tyr612 and Akt at
Ser473 (Figure S1).
Lastly, we investigated whether the phosphorylation levels of
LKB1 and AMPK is altered by Sirt6 knockdown with RGZ
treatment in AML12 mouse hepatocytes. RGZ increased
phosphorylation levels of LKB1 (Ser428) and AMPK (Thr172)
in the presence of FFA, and the knockdown of Sirt6 suppressed the
effects of RGZ on the phosphorylation of LKB1 and AMPK
(Figure 7), suggesting that Sirt6 regulates the phosphorylation of
LKB1 and AMPK.
Discussion
In this paper, we have demonstrated that RGZ improved
hepatic steatosis, accompanied by an elevation in adiponectin,
Sirt6 and its related targets, as well as AMPK phosphorylation,
both in vivo and in vitro. The protective effects of RGZ and other
TZDs against hepatic steatosis were previously reported in patients
with type 2 diabetes and nonalcoholic steatohepatitis [11,12,28].
Similarly, improvements in hepatic steatosis and oxidative stress
have been observed in rats with high fructose-induced meta-
bolic syndrome [13]. Thus, the beneficial effect of rosiglitazone
against hepatic steatosis was supported by a number of findings,
although the underlying functional mechanisms remained to be
established.
It is well known that TZD regulates insulin action, lipid and
glucose metabolism and energy homeostasis by impacting PPARc
and its transcriptional regulation [6,7]. RGZ significantly increases
the release of adiponectin, presumably acting through PPARc [17]
which activates AMPK, leading to stimulation of glucose utilization
Figure 5. Sirt6 knockdown diminished the effect of rosiglita-
zone (RGZ) to reduce hepatocyte lipid accumulation. Values of
triglyceride (TG) and free fatty acids (FFA) were normalized with respect
to protein concentrations. Data are means6SEM (n=6 per group).
*p,0.05 vs control (CON; white bar), {p,0.05 vs FFA alone.
doi:10.1371/journal.pone.0017057.g005
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action, TZD has been suggested to also control metabolic processes
via PPARc-independent mechanisms. RGZ is known to increase
AMPK activation by inhibition of complex I activity of the
respiratory chain, which results in an increase in the cellular
AMP:ATP ratio [16,30]. Here, we found that RGZ treatment
increased adiponectin, PPARa, PPARc and AMPK activation,
suggesting that these factors may be involved in the RGZ-mediated
amelioration of hepatic steatosis. RGZ likely acts through the
PPARc-induced increase in adiponectin and the subsequent
elevation of AMPK activity as well as PPARa via adiponectin
receptor 1 (Adipor1) and Adipor2, respectively. A recent paper
demonstrated that adenovirus-mediated expression of Adipor1 and
Adipor2 stimulated AMPK activation and PPARa signaling,
Figure 6. The effect of Sirt6 knockdown on expression of Sirt6 and related targets in hepatocytes. Gene expression of (A) adiponectin
(AdipoQ), (B) peroxisome proliferator-activated receptor alpha (Ppara), (C) PPAR gamma (Pparg), (D) Sirt6, (E) peroxisome proliferator-activated
receptor gamma coactivtor-1-a (Ppargc1a), and (F) forkhead box O1 (Foxo1). Expression levels were normalized with respect to those of b-actin (Actb).
(G) Representative western blots for Sirt6, peroxisome proliferator-activated receptor gamma coactivtor-1-a (PGC1- a), phosphorylated Foxo1 at
Ser249 (pFoxo1), Foxo1, and b-actin are shown. (H) Densitometric analysis of Sirt6, PGC1- a, and pFoxo1. The expression of Sirt6 and PGC1- a was
normalized to values for b-actin. Levels of phosphorylated Foxo1 at Ser249 were normalized to values for Foxo1. FFA, free fatty acids; RGZ,
rosiglitazone. Data are means6SEM (n=6 per group). *p,0.05 vs control (CON; white bar), {p,0.05 vs FFA alone.
doi:10.1371/journal.pone.0017057.g006
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TG in the livers of db/db mice [31].
We also observed up-regulation of Sirt6 and its potential
downstream targets, Ppargc1a and Foxo1, with RGZ treatment, in
vivo and in vitro. From these observations, we hypothesize that Sirt6
may be a key regulating target for RGZ to reduce hepatic fat
accumulation. To determine whether Sirt6 is causally related to
the development of hepatic steatosis and its amelioration by RGZ,
we directly inhibited Sirt6 by RNAi-mediated gene silencing in
AML12 mouse hepatocytes. The knockdown of Sirt6 aggravated
hepatocyte fat accumulation as shown by increased TG levels, and
suppressed the favorable effects of RGZ on hepatocyte steatosis. In
addition, Sirt6 knockdown suppressed gene expression of
Ppargc1a and Foxo1, and abolished the RGZ-mediated activation
of LBK1 and AMPK, suggesting that Ppargc1a, Foxo1, LKB1 and
AMPK may act as down-stream effectors of Sirt6. These data are
similar to previous findings for Sirt1 and LKB1/AMPK signaling.
Sirt1 is known to act as upstream of LKB1/AMPK signaling and
LKB1 is required for AMPK activation by Sirt1 in HepG2 cells
and in the mouse liver [23]. Sirt1 regulation of AMPK signaling
may be an indirect effect of Sirt1-mediated deacetylation of LKB1,
and its subsequent translocation to the cytoplasm where it is
activated [24]. Sirt1 also deacetylates other targets, such as
Ppargc1a and Foxo1 [32,33], and this deacetylation and
subsequent activation enables these mediators to participate in
Sirt1-AMPK-dependent metabolic regulation. Given our findings
that Sirt6 knockdown suppressed activation of LKB1 and AMPK,
we hypothesize that Sirt6 also acts as upstream of AMPK
signaling. However, our data do not exclude the possibility that the
AMPK signaling pathway also controls the expression and activity
of Sirt6. In mouse skeletal muscles and C2C12 skeletal muscle
cells, AMPK increases cellular NAD
+ levels, leading to elevated
Sirt1 activity [34,35]. The increased Sirt1 activity results in
deacetylation and modulation of activities of Sirt1 downstream
targets. These findings support a role for AMPK also in
stimulating the activities of Sirt1 and Sirt6 via an increase in
cellular NAD
+ levels. Considering that AMPK regulation on Sirt1
has up to date been exclusively reported in skeletal muscles, it is
possible that the interdependence of Sirt1/6 and AMPK is tissue-
specific. The relationship between Sirt1/6 and AMPK is more
likely dominated by Sirt1/6 regulation on LKB1/AMPK
signaling, especially in the liver.
Over the past several years, the role of sirtuins has expanded to
that of metabolic regulators, in addition to their function as
NAD
+-dependent deacetylases. Overexpression of Sirt1 and Sirt6
was recently reported to improve glucose control, hepatic steatosis
and inflammation [22,26]. Conversely, liver-specific Sirt1 knock-
out mice developed hepatic steatosis, hepatic inflammation, and
endoplasmic reticulum stress [21]. Similar aggravation of hepatic
steatosis was also observed in liver-specific Sirt6 knockout mice
[36]. And, the Sirt6 knockout mice showed severe hypoglycemia
by enhancing insulin signaling and subsequent glucose uptake
[37]. Similarly, mediators involved in insulin signaling and glucose
uptake were increased by Sirt6 knockdown in AML12 mouse
hepatocytes. Treatment of HepG2 cells and mice with Sirt1
activators (e.g., resveratrol and SRT1720) showed therapeutic
Figure 7. The effect of Sirt6 knockdown on phosphorylation of LKB1 and AMP-activated protein kinase (AMPK) in hepatocytes. (A)
Representative western blots for phosphorylated LKB1 at Ser428 (pLKB1), LKB1, phosphorylated AMPKa at Thr172 (pAMPKa), pAMPKa, and b-actin.
(B) Densitometric analysis of pLKB1 and pAMPKa. Levels of phosphorylated LKB1 at Ser428 and AMPKa at Thr172 were normalized to values for LKB1
and AMPKa, respectively. FFA, free fatty acids; RGZ, rosiglitazone. Data are means6SEM (n=6 per group). *p,0.05 vs control (CON; white bar),
{p,0.05 vs FFA alone.
doi:10.1371/journal.pone.0017057.g007
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activators, RGZ administration increased Sirt6 expression and
phosphorylation levels of LKB1 and AMPK, and provided
protection from hepatic steatosis, suggesting that RGZ may act
as a Sirt6 activator and a therapeutic strategy for NAFLD.
Regarding the involvement of Sirt1 in the RGZ’s action, a recent
paper using a mouse model of alcoholic fatty liver showed that
RGZ improves alcoholic fatty liver and stimulates adiponectin-
Sirt1-AMPK signaling [40]. Moreover, in rat hepatoma cells,
adiponectin activated AMPK signaling by up-regulating Sirt1
[40]. These findings were the first to demonstrate the involvement
of Sirt1 in the protective action of RGZ against alcoholic fatty
liver. The regulatory effects of adiponectin, Sirt1, and AMPK
found in rat hepatoma cells are intriguing, but, future studies are
needed to investigate whether this regulation is RGZ-dependent.
In light of previous findings, our data demonstrating the
involvement of Sirt6 in the RGZ-mediated protection of hepatic
steatosis suggest that Sirt6 may have functional similarities with
Sirt1 as a metabolic regulator. Both Sirt1 and Sirt6 are essential
for survival as demonstrated by knockout of Sirt1 or Sirt6 that
resulted in postnatal death in mice [25,41]. Moreover, both are
located in the nucleus [18], implying their possible involvement in
transcriptional regulation of genes modulating metabolic process-
es. Sirt1 and Sirt6 also both show protective effects against hepatic
steatosis [22,26]. Considering the previous observations as well as
our findings, it can be speculated that both Sirt1 and Sirt6 are
involved in the RGZ-mediated amelioration of hepatic steatosis.
However, how and what extents the interaction between Sirt1 and
Sirt6 affects and which sirtuin contributes more to the RGZ’s
action is not yet completely known. A provocative observation was
reported that Sirt1 is involved in the transcriptional regulation of
Sirt6 by forming a complex with Foxo3a and nuclear respiratory
factor 1 on the Sirt6 promoter [36]. However, Sirt6 knockdown
had no regulatory effect on Sirt1 mRNA expression in AML12
mouse hepatocytes. Additional studies are required to investigate
how Sirt1 or Sirt6 interacts each other or with other sirtuins, and
to determine how the involvement of specific types of sirtuins in
the metabolic processes is regulated. In addition, more studies are
needed to investigate metabolic regulation by Sirt6 and its
underlying mechanisms.
In this study, we aimed to elucidate whether Sirt6 is involved in
RGZ-mediated protection against hepatic steatosis. Consistent
with the previous reports, our findings provide evidence that RGZ
improves hepatic steatosis. Interestingly, we found that the RGZ-
mediated beneficial effect against hepatic steatosis is dependent on
the Sirt6-AMPK pathway. Our study is the first to demonstrate
the involvement and importance of Sirt6 in RGZ-mediated
protection against hepatic steatosis. The metabolic effects of
RGZ are mediated by the induction of a genetic network
controlling fatty acid oxidation. Regulation occurs by multiple
mechanisms that involve the direct deacetylation of Ppargc1a/
PGC1-a, Foxo1, and other targets, as well as the indirect
stimulation of AMPK signaling. Our findings emphasize that
Sirt6 is involved in RGZ-mediated metabolic regulation. Taken
together, these findings support the improvement of hepatic
steatosis by RGZ by activation of the Sirt6-AMPK pathway, and
suggest Sirt6 as a therapeutic target for hepatic steatosis.
Supporting Information
Figure S1 The effect of Sirt6 knockdown on mediators
involved in insulin signaling and glucose uptake in
hepatocytes. Representative western blots for phosphorylated
insulin receptor (IR) at Tyr1158, Tyr1162, and Tyr1163
(pIR(Tyr)), IR, phosphorylated IR substrate1 (IRS1) at Tyr612,
IRS1, phosphorylated Akt at Ser473, Akt, glucose transporter 1
(GLUT1), and b-actin. FFA, free fatty acids; RGZ, rosiglitazone.
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